Terms: = Skin cancer AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF AND Treatment
70 results:
1. Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
Delzenne G; Boileau M; Jamme P; Farchi O; Mortier L
Melanoma Res; 2024 Apr; 34(2):182-185. PubMed ID: 38329225
[TBL] [Abstract] [Full Text] [Related]
2. Mosaic BRAF Fusions Are a Recurrent Cause of Congenital Melanocytic Nevi Targetable by MAPK Pathway Inhibition.
Martin SB; Polubothu S; Bruzos AL; Kelly G; Horswell S; Sauvadet A; Bryant D; Zecchin D; Riachi M; Michailidis F; Sadri A; Muwanga-Nanyonjo N; Lopez-Balboa P; Knöpfel N; Bulstrode N; Pittman A; Yeh I; Kinsler VA
J Invest Dermatol; 2024 Mar; 144(3):593-600.e7. PubMed ID: 37716647
[TBL] [Abstract] [Full Text] [Related]
3. miR-224-5p acts as a tumour suppressor and reverses the resistance to BRAF inhibitor in melanoma through directly targeting PAK4 to block the MAPK pathway.
Liu Y; Ruan H; Lu F; Peng H; Luan W
Pathol Res Pract; 2023 Sep; 249():154772. PubMed ID: 37611431
[TBL] [Abstract] [Full Text] [Related]
4. Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies.
Najem A; Krayem M; Sabbah S; Pesetti M; Journe F; Awada A; Désaubry L; Ghanem GE
Cells; 2023 Jul; 12(14):. PubMed ID: 37508519
[TBL] [Abstract] [Full Text] [Related]
5. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in
de Braud F; Dooms C; Heist RS; Lebbe C; Wermke M; Gazzah A; Schadendorf D; Rutkowski P; Wolf J; Ascierto PA; Gil-Bazo I; Kato S; Wolodarski M; McKean M; Muñoz Couselo E; Sebastian M; Santoro A; Cooke V; Manganelli L; Wan K; Gaur A; Kim J; Caponigro G; Couillebault XM; Evans H; Campbell CD; Basu S; Moschetta M; Daud A
J Clin Oncol; 2023 May; 41(14):2651-2660. PubMed ID: 36947734
[TBL] [Abstract] [Full Text] [Related]
6. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of craf and MEK1/2.
Wang P; Jia X; Lu B; Huang H; Liu J; Liu X; Wu Q; Hu Y; Li P; Wei H; Liu T; Zhao D; Zhang L; Tian X; Jiang Y; Qiao Y; Nie W; Ma X; Bai R; Peng C; Dong Z; Liu K
Signal Transduct Target Ther; 2023 Mar; 8(1):96. PubMed ID: 36872366
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of New Quinolone-Based Diarylamides as Potent B-RAF
Kim HJ; Park JW; Seo S; Cho KH; Alanazi MM; Bang EK; Keum G; El-Damasy AK
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834628
[TBL] [Abstract] [Full Text] [Related]
8. Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature.
Lee CL; Holter S; Borgida A; Dodd A; Ramotar S; Grant R; Wasson K; Elimova E; Jang RW; Moore M; Kim TK; Khalili K; Moulton CA; Gallinger S; O'Kane GM; Knox JJ
World J Gastroenterol; 2022 Dec; 28(45):6421-6432. PubMed ID: 36533108
[TBL] [Abstract] [Full Text] [Related]
9. BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS
McGrail K; Granado-Martínez P; Esteve-Puig R; García-Ortega S; Ding Y; Sánchez-Redondo S; Ferrer B; Hernandez-Losa J; Canals F; Manzano A; Navarro-Sabaté A; Bartrons R; Yanes O; Pérez-Alea M; Muñoz-Couselo E; Garcia-Patos V; Recio JA
Nat Commun; 2022 Nov; 13(1):7113. PubMed ID: 36402789
[TBL] [Abstract] [Full Text] [Related]
10. HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.
Sasame J; Ikegaya N; Kawazu M; Natsumeda M; Hayashi T; Isoda M; Satomi K; Tomiyama A; Oshima A; Honma H; Miyake Y; Takabayashi K; Nakamura T; Ueno T; Matsushita Y; Iwashita H; Kanemaru Y; Murata H; Ryo A; Terashima K; Yamanaka S; Fujii Y; Mano H; Komori T; Ichimura K; Cahill DP; Wakimoto H; Yamamoto T; Tateishi K
Clin Cancer Res; 2022 Jun; 28(11):2425-2439. PubMed ID: 35344043
[TBL] [Abstract] [Full Text] [Related]
11. BRAF Inhibitors Reprogram cancer-Associated Fibroblasts to Drive Matrix Remodeling and Therapeutic Escape in Melanoma.
Liu T; Zhou L; Xiao Y; Andl T; Zhang Y
Cancer Res; 2022 Feb; 82(3):419-432. PubMed ID: 35064015
[TBL] [Abstract] [Full Text] [Related]
12. Targetable BRAF and raf1 Alterations in Advanced Pediatric cancers.
Rankin A; Johnson A; Roos A; Kannan G; Knipstein J; Britt N; Rosenzweig M; Haberberger J; Pavlick D; Severson E; Vergilio JA; Squillace R; Erlich R; Sathyan P; Cramer S; Kram D; Ross J; Miller V; Reddy P; Alexander B; Ali SM; Ramkissoon S
Oncologist; 2021 Jan; 26(1):e153-e163. PubMed ID: 32918774
[TBL] [Abstract] [Full Text] [Related]
13. Systemic review on B-Raf
Chavda J; Bhatt H
Eur J Med Chem; 2020 Nov; 206():112675. PubMed ID: 32798788
[TBL] [Abstract] [Full Text] [Related]
14. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract] [Full Text] [Related]
15. Malignant melanoma with areas of rhabdomyosarcomatous differentiation arising in a giant congenital nevus with raf1 gene fusion.
Baltres A; Salhi A; Houlier A; Pissaloux D; Tirode F; Haddad V; Karanian M; Ysmail-Dahlouk S; Boukendakdji F; Dahlouk D; Allaoua F; Metref M; Djeridane A; Fraitag S; de la Fouchardière A
Pigment Cell Melanoma Res; 2019 Sep; 32(5):708-713. PubMed ID: 30945443
[TBL] [Abstract] [Full Text] [Related]
16. Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - c-raf.
Blair CM; Walsh NM; Littman BH; Marcoux FW; Baillie GS
BMC Cancer; 2019 Mar; 19(1):266. PubMed ID: 30909892
[TBL] [Abstract] [Full Text] [Related]
17. Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-raf1 fusion.
McEvoy CR; Xu H; Smith K; Etemadmoghadam D; San Leong H; Choong DY; Byrne DJ; Iravani A; Beck S; Mileshkin L; Tothill RW; Bowtell DD; Bates BM; Nastevski V; Browning J; Bell AH; Khoo C; Desai J; Fellowes AP; Fox SB; Prall OW
J Clin Invest; 2019 May; 129(5):1940-1945. PubMed ID: 30835257
[TBL] [Abstract] [Full Text] [Related]
18. SUV39H1/DNMT3A-dependent methylation of the RB1 promoter stimulates PIN1 expression and melanoma development.
Kim G; Kim JY; Lim SC; Lee KY; Kim O; Choi HS
FASEB J; 2018 Oct; 32(10):5647-5660. PubMed ID: 29750576
[TBL] [Abstract] [Full Text] [Related]
19. The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E-transformed cells.
Furlan T; Khalid S; Nguyen AV; Günther J; Troppmair J
Mol Oncol; 2018 Jun; 12(6):869-882. PubMed ID: 29624862
[TBL] [Abstract] [Full Text] [Related]
20. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
[TBL] [Abstract] [Full Text] [Related]
[Next]